COMPOUNDS USED AS ATR KINASE INHIBITORS Russian patent published in 2019 - IPC C07D487/04 A61K31/519 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound of formula I or a pharmaceutically acceptable salt thereof, as well as versions of a method for production thereof. In a compound of formula I I, R¹ is -C(J¹)₂CN or halogen; R⁹ is H; each J¹ independently represents H or C_1-2alkyl; or two J¹, together with the carbon atom to which they are bonded, form 3-4-member carbocyclic ring; R² is H; halogen; -CN; NH₂; C_1-2alkyl optionally substituted with 0-3 fluoro; or C_1-3aliphatic chain, where up to two methylene links of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)- or -S(O)_n-; R³ is H; halogen; C_1-4alkyl, optionally substituted with 1-3 halogens; C_3-4cycloalkyl; -CN; or C_1-3aliphatic chain, where up to two methylene links of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)- or -S(O)_n-; R⁴ is Q¹ or C_1-10aliphatic chain, where up to four methylene links of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)- or -S(O)_n-; each R⁴ optionally substituted with 0-5 J^Q; or R³ and R⁴, taken together with atoms with which they are bonded, form 5-6-member non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen and sulfur; ring formed by R³ and R⁴, optionally substituted with 0-3 J^Z; Q¹ is 3-7-member fully saturated, partially unsaturated or aromatic monocyclic ring, wherein 3-7-member ring has 0-3 heteroatoms selected from oxygen, nitrogen and sulfur; or 7-12-member fully saturated, partially unsaturated or aromatic bicyclic ring, wherein 7-12-member fully saturated or partially unsaturated bicyclic ring has 0-5 heteroatoms selected from oxygen, nitrogen and sulfur, and 7-12-member aromatic bicyclic ring has 1-5 heteroatoms selected from oxygen, nitrogen and sulfur; each J^z independently represents C_1-6alkyl, =O, halogen or →O; each J^Q independently represents -CN; halogen; =O; Q²; or C_1-8aliphatic chain, where up to three methylene links of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)- or -S(O)_n-; each J^Q optionally substituted with 0-3 J^R; or two J^Q on the same atom, taken together with the atom to which they are bonded, form 3-6-member ring having 0-2 heteroatoms selected from oxygen, nitrogen and sulfur; where ring formed by two J^Q, optionally substituted with 0-3 J^X; or two J^Q, together with Q¹, form 6-10-member saturated or partially unsaturated bridged ring system; each Q² independently represents 3-7-member fully saturated, partially unsaturated or aromatic monocyclic ring, wherein 3-7-member fully saturated or partially unsaturated monocyclic ring has 0-3 heteroatoms selected from oxygen, nitrogen and sulfur, and 3-7-member aromatic monocyclic ring has 1-3 heteroatoms selected from oxygen, nitrogen and sulfur; or 7-12-member fully saturated, partially unsaturated or aromatic bicyclic ring, 7-12-member fully saturated or partially unsaturated bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen and sulfur, and 7-12-member aromatic bicyclic ring has 1-5 heteroatoms selected from oxygen, nitrogen and sulfur; each J^R independently represents -CN; halogen; =O; →O; Q³; or C_1-6aliphatic chain, where up to three methylene links of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)- or -S(O)_n-; each J^R optionally substituted with 0-3 J^T; or two J^R on the same atom, together with the atom to which they are bonded, form 3-6-member ring having 0-2 heteroatoms selected from oxygen, nitrogen and sulfur; where ring formed by two J^R, optionally substituted with 0-3 J^X; or two J^R, together with Q², form 6-10-member saturated or partially unsaturated bridged ring system; each Q³ independently represents 3-7-member fully saturated monocyclic ring, wherein 3-7-member fully saturated monocyclic ring has 0-2 heteroatoms selected from oxygen and nitrogen; or 7-12-member fully saturated spirocyclic or condensed bicyclic ring, wherein 7-12-member fully saturated spirocyclic ring has 1-2 heteroatoms selected from oxygen and nitrogen; each J^X independently represents -CN; =O; halogen; or C_1-4aliphatic chain, where up to two methylene links of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)- or -S(O)_n-; each J^T independently represents halogen, -CN; →O; =O; -OH; C_1-6aliphatic chain, where up to two methylene links of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)- or -S(O)_n-; or 3-6-member non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen and sulfur; each J^T optionally substituted with 0-3 J^M; or two J^T on the same atom, together with the atom to which they are bonded, form 3-6-member ring having 0-2 heteroatoms selected from oxygen, nitrogen and sulfur; or two J^T together with Q³, form 6-10-member saturated bridged ring system, optionally containing 0-2 heteroatoms selected from oxygen and nitrogen; each J^M independently represents halogen or C_1-6an aliphatic group; n equals 0, 1 or 2; and each R independently represents H or C_1-4aliphatic group.

EFFECT: compounds have the properties of an ATR protein kinase inhibitor and can be used for treating cancer, for example, colon and rectal cancer.

74 cl, 7 tbl, 22 ex